MX2019005742A - Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. - Google Patents
Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.Info
- Publication number
- MX2019005742A MX2019005742A MX2019005742A MX2019005742A MX2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- albumin
- compound
- pharmaceutically acceptable
- binding psma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/08—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Radiology & Medical Imaging (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425810P | 2016-11-23 | 2016-11-23 | |
| PCT/US2017/063182 WO2018098390A1 (en) | 2016-11-23 | 2017-11-24 | Albumin-binding psma inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019005742A true MX2019005742A (es) | 2019-09-13 |
Family
ID=60812130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005742A MX2019005742A (es) | 2016-11-23 | 2017-11-24 | Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11147889B2 (enExample) |
| EP (1) | EP3544960A1 (enExample) |
| JP (1) | JP7167021B2 (enExample) |
| CN (1) | CN109982998A (enExample) |
| BR (1) | BR112019010206A2 (enExample) |
| CA (1) | CA3043619A1 (enExample) |
| MX (1) | MX2019005742A (enExample) |
| WO (1) | WO2018098390A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018352731B2 (en) * | 2017-10-22 | 2023-10-05 | Provincial Health Services Authority | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
| WO2019246445A1 (en) * | 2018-06-20 | 2019-12-26 | The Research Foundation For The State University Of New York | Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same |
| EP3880253A1 (en) | 2018-11-14 | 2021-09-22 | Noria Therapeutics, Inc. | Thioamide-containing compositions and methods of use thereof |
| WO2020108753A1 (en) * | 2018-11-28 | 2020-06-04 | ITM Isotopen Technologien München AG | Novel tumor antigen binding agents and uses thereof |
| CA3136979A1 (en) | 2019-04-17 | 2020-10-22 | Provincial Health Services Authority | Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer |
| WO2020252598A1 (en) | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| TWI908773B (zh) | 2020-03-04 | 2025-12-21 | 日商日本醫事物理股份有限公司 | 化合物及放射性標誌化合物 |
| JP7894086B2 (ja) * | 2020-05-06 | 2026-07-23 | コーネル ユニヴァーシティー | 銅含有セラグノスティック化合物及びその使用の方法 |
| CN116829541A (zh) * | 2020-12-04 | 2023-09-29 | 加利福尼亚大学董事会 | 肽受体放射性核素治疗 |
| US20240018110A1 (en) * | 2020-12-16 | 2024-01-18 | The University Of British Columbia | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| CN114685599A (zh) * | 2020-12-30 | 2022-07-01 | 南京江原安迪科正电子研究发展有限公司 | 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途 |
| CN116940557A (zh) * | 2021-03-04 | 2023-10-24 | 日本医事物理股份有限公司 | 化合物及放射性标记化合物 |
| US20240174622A1 (en) | 2021-03-04 | 2024-05-30 | Nihon Medi-Physics Co., Ltd. | Compound and radioactive labeling compound |
| CA3244865A1 (en) * | 2022-03-04 | 2023-09-07 | Provincial Health Services Authority | RADIOLABELLED COMPOUNDS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN |
| WO2024126687A1 (en) * | 2022-12-16 | 2024-06-20 | Silence Therapeutics Gmbh | Nucleic acids conjugated to an albumin binding moiety |
| EP4667019A1 (en) * | 2023-02-16 | 2025-12-24 | Norroy Bioscience Co., Ltd. | Psma-targeted radiopharmaceutical, and synthesis and use thereof |
| CN116217505B (zh) * | 2023-03-17 | 2024-10-01 | 南京医科大学 | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0621973D0 (en) * | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| EP4420730A3 (en) | 2009-03-19 | 2024-11-13 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
| JP5843338B2 (ja) | 2011-08-05 | 2016-01-13 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 放射標識された前立腺特異的膜抗原阻害剤 |
| US10011632B2 (en) | 2011-08-22 | 2018-07-03 | Siemens Medical Solutions Usa, Inc. | PSMA imaging agents |
| CN106061981A (zh) * | 2013-11-06 | 2016-10-26 | 索尔斯蒂斯生物有限公司 | 具有二硫化物基团的多核苷酸构建体 |
| WO2015073678A1 (en) * | 2013-11-14 | 2015-05-21 | Endocyte, Inc. | Compounds for positron emission tomography |
| US10112974B2 (en) * | 2014-08-24 | 2018-10-30 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer |
| PL3356385T3 (pl) * | 2015-09-30 | 2021-06-28 | Deutsches Krebsforschungszentrum | Tagowane 18F inhibitory antygenu błonowego specyficznego dla gruczołu krokowego (PSMA) i ich zastosowanie jako środków do obrazowania w nowotworze gruczołu krokowego |
| KR20250057132A (ko) * | 2016-03-22 | 2025-04-28 | 더 존스 홉킨스 유니버시티 | 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 |
| SG11201811482YA (en) * | 2016-06-23 | 2019-01-30 | Univ Cornell | Double targeted constructs to affect tumor kill |
| DE102016122273B4 (de) | 2016-11-18 | 2018-06-21 | Abx Advanced Biochemical Compounds Gmbh | Präkursoren für die Radiofluorierung |
-
2017
- 2017-11-24 CN CN201780071927.6A patent/CN109982998A/zh active Pending
- 2017-11-24 BR BR112019010206A patent/BR112019010206A2/pt not_active Application Discontinuation
- 2017-11-24 JP JP2019527426A patent/JP7167021B2/ja not_active Expired - Fee Related
- 2017-11-24 EP EP17821755.0A patent/EP3544960A1/en not_active Withdrawn
- 2017-11-24 MX MX2019005742A patent/MX2019005742A/es unknown
- 2017-11-24 WO PCT/US2017/063182 patent/WO2018098390A1/en not_active Ceased
- 2017-11-24 CA CA3043619A patent/CA3043619A1/en active Pending
- 2017-11-24 US US16/349,756 patent/US11147889B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019010206A2 (pt) | 2019-09-03 |
| US11147889B2 (en) | 2021-10-19 |
| EP3544960A1 (en) | 2019-10-02 |
| JP2019535754A (ja) | 2019-12-12 |
| WO2018098390A1 (en) | 2018-05-31 |
| CN109982998A (zh) | 2019-07-05 |
| JP7167021B2 (ja) | 2022-11-08 |
| CA3043619A1 (en) | 2018-05-31 |
| US20200061218A1 (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| CY1120480T1 (el) | Ενωσεις πυραζολοπυριμιδινης | |
| CY1125021T1 (el) | Κιναζολινες ως αναστολεις διαυλων ιοντων καλιου | |
| PH12022551574A1 (en) | Egfr inhibitors | |
| MX2023004309A (es) | Inhibidores de quinasa alk2 que contienen imidazol. | |
| MX2018008168A (es) | Inhibidores de antigenos de membrana especificos de la prostata (psma) basados en la urea para imaginologia y terapia. | |
| PH12018502227A1 (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| WO2011116299A3 (en) | Myeloid derived suppressor cell inhibiting agents | |
| BR112012029994A2 (pt) | composto heterocíclicos como inibidores de janus quinase | |
| GEP20237479B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
| EA201170617A1 (ru) | Пиразолиламинопиридины в качестве ингибиторов fak | |
| CY1118721T1 (el) | Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης | |
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| EA201170872A1 (ru) | Ингибиторы протеинкиназы | |
| EA201290237A1 (ru) | Киназные ингибиторы | |
| SG10201407453TA (en) | Kinase inhibitors | |
| EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
| MX2012013206A (es) | Inhibidores de quinasa biciclica fusionada. | |
| MX2012001420A (es) | Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus. | |
| NI200900183A (es) | Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer. | |
| BR112019002560A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método |